The initial success of the copyright undeniably reshaped the medication landscape, but investing in companies heavily reliant on unbranded versions presents a complex picture. While early profits were impressive, the expiration of patents and the appearance of discounted alternatives have eroded market share. Thus, a thorough analysis of current fi